For patients with acute promyelocytic leukaemia (APL), all-trans retinoic acid (ATRA) and chemotherapy is the standard of care. A multicentre, phase III trial has now compared ATRA plus chemotherapy with ATRA plus arsenic trioxide for low-to-intermediate risk patients with APL. The ATRA plus arsenic trioxide regimen demonstrated non-inferiority compared with standard therapy and was associated with less haematological toxicity and fewer infections, but greater hepatic toxicity.
References
Lo-Coco, F. et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369, 111–121 (2013)
Rights and permissions
About this article
Cite this article
ATRA and arsenic trioxide treatment for leukaemia. Nat Rev Clin Oncol 10, 487 (2013). https://doi.org/10.1038/nrclinonc.2013.141
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.141
